Table 1.

Characteristics of randomized controlled trials included in the meta-analysis

Reference	Year of publication	Trial Phase	Cancer Type	Follow-up (month)	Total cisplatin dose(mg/m2)	Cisplatin Arm				Non-cisplatin Arm
						Regimen	No. of Patients	Second Cancers (No.)	Leukemia (No.)	Regimen	No. of Patients	Second Cancers (No.)	Leukemia (No.)
Ajani et al..	2008	III	Anal	Median 30.1	Median 300	Fluorouracil, cisplatin and radiotherapy	320	1		Fluorouracil, mitomycin and radiotherapy	324	0
Basu et al	2016	II	Cervical	Median 29.2	Median 200	Cisplatin and radiotherapy	105	0		Interferon-alpha, retinoic acid and radiotherapy	104	1
Booton et al	2006	III	Lung	Median 17.4	Median 200	Mitomycin, ifosfamide and cisplatin or mitomycin, vinblastine and cisplatin	210	0		Docetaxel and carboplatin	212	1
Cohen et al	2014	III	Head and neck	Minimum 30	Median 150	Docetaxel, cisplatin and fluorouracil, followed by docetaxel, fluorouracil, and hydroxyurea plus radiotherapy	138	2		Docetaxel, fluorouracil, and hydroxyurea plus radiotherapy	135	1
Conroy et al	2014	II/III	Oesophageal	Median 25.3	Median 300	Fluorouracil, cisplatin and radiotherapy	133	7		Fluorouracil, leucovorin, oxaliplatin and radiotherapy	134	8
Cortelazzo et al	2012	III	Lymphoma	Median 27.7	Planned 300	Rituximab, cyclophosphamide, Ara-C, methotrexate, etoposide, cisplatin and autografting	121	0		Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone	127	0
du Bois et al	2003	III	Ovarian	Mean: 48.5 for cisplatin arm 49.9 for non-cisplatin arm	Median 441.6	Paclitaxel and cisplatin	386	9	0	Paclitaxel and carboplatin	397	9	0
Fleming et al	2004	III	Endometrial	Median 61 for alive patients	Planned 350	Doxorubicin and cisplatin	156	0	0	Doxorubicin and paclitaxel	157	1	1
Fountzilas et al	2004	III	Head and neck	Median 60	Median 270	Cisplatin and radiotherapy	45	1		Carboplatin and radiotherapy	38	1
Garden et al	2004	II	Head and neck	Median: 31.2–34.8	Median 100/140	Cisplatin, fluorouracil and radiotherapy vs cisplatin, paclitaxel and radiotherapy	155	6		Hydroxyurea, fluorouracil and radiotherapy	76	1
Geyer et al	2004	II	Brain	Median 79.2	Not reported	Vincristine, cisplatin, cyclophosphamide and etoposide	149	3	3	Vincristine, carboplatin, ifosfamide and etoposide	135	1	1
Harari et al	2014	II	Head and neck	Median 52.8	Median 180	Cisplatin, cetuximab and radiotherapy	97	4		Docetaxel, cetuximab and radiotherapy	106	12
Hiesiger et al	1995	Not reported	Brain	Median 26.5 for alive patients	Planned 720	Cisplatin	125	0	0	PCNU	145	1	1
Homma et al	2004	II	Head and neck	Median 63	Median 64	Cisplatin and radiotherapy	59	7		Carboplatin and radiotherapy	60	7
Intragumtornchai et al	2000	Not reported	Lymphoma	Median 36	Maximum 400	Etoposide, methylprednisolone, high-dosecytarabine, cisplatin, high-dose therapy and autologous peripheral blood progenitor cell transplantation	23	1	1	Cyclophosphamide,doxorubicin, vincristine and prednisolone	25	0	0
James et al	2013	III	Anus	Median 61.2	Planned 120/120/240	Cisplatin, fluorouracil and radiotherapy vs Mitomycin, fluorouracil, radiotherapy followed by cisplatin and fluorouracil vs Cisplatin, fluorouracil, radiotherapy followed by cisplatin and fluorouracil	694	17		Mitomycin, fluorouracil and radiotherapy	246	3
Jennings et al	2002	II	Glioma	Maximum 37	Median 300	Cisplatin, etoposide, cyclophosphamide and vincristine	31	0	0	Carboplatin, etoposide, and vincristine	32	1	1
Nicoletto et al	2007	Not reported	Ovarian	Median 178	Median 375	Cisplatin and cyclophosphamide	80	0		Adriamycin and cyclophosphamide	81	2
Nielsen et al	2000	III	Breast	Mean 17	Median 518	Epirubicin and cisplatin	74	3	3	Epirubicin	81	0	0
Olasz et al	2004	Not reported	Head and neck	Median 52	Median 120	Bleomycin, vincristine, methotrexate and cisplatin	19	1		Bleomycin, vincristine and methotrexate	19	1
Sirohi et al	2010	III	Breast	Median 112	Median 360	Epirubicin, cisplatin and 5-fluorouracil	172	3		5-fluorouracil, epirubicin and cyclophosphamide	177	11
Sutton et al	2000	III	Uterus	Maximum 24	Median 320	Ifosfamide and cisplatin	90	1	1	Ifosfamide	101	0	0
Taylor et al	1994	III	Ovarian	Median 108	Median 331.2	Cisplatin	64	0		Carboplatin	67	0
Tropé et al	1996	Not reported	Ovarian	Minimum 120	Planned 500	Cisplatin, doxorubicin and melphalan	143	4	4	Doxorubicin and melphalan	153	2	2
Tsimberidou et al	2002	Not reported	Lymphoma	Median 70.8	Planned 100	CHOD-Bleo, ESHAP, and NOPP	69	1	1	Fludarabine, mitoxantrone, and dexamethasone	1	73	1
Wada et al	1996	Not reported	Lung	Median 60	Mean 56.5	Cisplatin, vindesine, tegafur and uracil	109	3		Tegafur and uracil	103	2
Wadler et al	1996	III	Ovarian	Median 156 for alive patients	Median 580	Cyclophosphamid, hexamethylmelamine, doxorubicin, and cisplatin	126	0		Melphalan	118	1
Williams et al	1985	Not reported	Ovarian	Median 45	Planned 400	Cisplatin, doxorubicin, cyclophosphamide	40	1	1	Chlorambucil	44	0	0

CHOD-Bleo cyclophosphamide, Doxorubicin, Vincristine, Bleomycin and Dexamethasone. ESHAP Etoposide, Methylprednisolone, Cytarabine and Cisplatin. NOPP Mitoxantrone, Vincristine, Procarbazine and Prednisone